Skip to content
Valuentum

Valuentum

Exclusive Analysis for the Discerning Investor

  • Membership
  • Home
  • Newsletters
  • High Yield
  • Exclusive
  • Stocks
  • Dividends
  • Advisers
  • Valuations
  • About Us

First Gene-Editing Therapy Coming to Market; Reiterating Our Positive Stance on Vertex Pharma

January 1, 1970 by Brian Nelson
Categories Member Articles Tags BEAM, BLUE, CRSP, DTIL, EDIT, GRPH, NTLA, VERV, VRTX
Dividend Increases/Decreases for the Week of November 17
Oracle’s “Business Is Good and Getting Better”
 
 
Forgot Password

Newsletters/Portfolios

Valuentum's Dividend Growth Newsletter Portfolio

Valuentum's Best Ideas Newsletter Portfolio

Order the Exclusive Publication!

Order the High-Yield Dividend Newsletter!

Dividend Cushion

Efficacy

Calculation

Dividend-Adjusted Leverage

White Paper

Stock Screens

How to Filter Data in Microsoft Excel Like a Pro

Download Weekly Stock Screener (xls)

The Quarterly DataScreener

Products & Tools

Financial Advisor (GOLD LEVEL) Publications

Order Value Trap

Order Value Trap, second edition

Value Trap

Order Paperback Copy

BookLife Review

BlueInk Review

Foreword Review

Readers' Favorite Review

Axiom Bronze

Praise

The Buying Index, VBI

Value and Momentum Within Stocks, Too (2017)

The Case for the Valuentum Style of Investing (2012)

Investing's Odd Couple: Value and Momentum (2013)

Stock-Selection Methodology, the Valuentum Buying Index (2011)

Why Valuentum Buying Index Ratings Matter (2014)

Footer

  • Home
  • About Us
  • Disclaimer
  • Advertise
  • Careers

Footer 2

  • Contact
  • Logout
  • Join Now
  • Privacy Policy
  • Terms & Conditions
© Copyright 2011-2026 Valuentum Securities Inc - Built with GeneratePress